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Abstract 
  The standard treatment of hypothyroidism is with levothyroxine (LT4). In the humans, 
the LT4 activates T4 to triiodothyronine (T3). However, there is a reported evidence that 
desiccated bovine thyroid (Armour Thyroid) is a better option as it has fewer side effects, though 
T3 is not fully reinstated in LT4-treated patients. On the other hand, desiccated thyroid extract 
(DTE) is a form of combination therapy in which the LT4/LT3 ratio is 4:1; the mean daily dose 
of DTE required to standardize serum TSH contains 11 mcg T3, but some patients may require 
higher doses. DTE does not have formal oversight by the FDA and reliability of T4 and T3 
contents is supervised only by the manufacturers (T et al., 2020). The purpose of this paper is to 
evaluate the efficacy of levothyroxine and comparison to DTE to guide the treatment of a 42-
year-old female diagnosed with hypothyroidism. Currently, levothyroxine is a drug of choice in 
managing hypothyroidism. However, research will be reviewed to determine whether this 
intervention is the better choice or considerations should be made to switch to DTE. Finding 
suggest levothyroxine monotherapy itself has proven to manage hypothyroidism while there is 
no significant effect in adding DTE in management of hypothyroidism. 
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Background 
According to Armstrong et al. (2019), hypothyroidism is known to be a condition 
whereby the thyroid gland  produces inadequate thyroid hormone. The major cause of 
hypothyroidism is autoimmune thyroiditis, an inflammation that affect thyroid gland cells 
causing  damage. This may cause the patient’s own immune system to weaken. It affects a large 
number of cells of the thyroid gland thus, less production of the thyroid hormones (West & Felz, 
2020). Signs and symptoms of hypothyroidism include “fatigue, weakness, weight gain or 
increased difficulty losing weight, coarse dry hair, dryness, rough pale skin, hair loss, cold 
intolerance, muscle cramps as well as frequent muscle aches, constipation ,depression, 
irritability, memory loss, abnormal menstrual cycles, and decreased libido” (West & Felz, 2020). 
In general hypothyroidism is defined as an endocrine disorder with under-production of thyroid 
hormone (Armstrong et al., 2019). 
Evidence indicates that a large population is affected with hypothyroidism and it is 
common especially in women and older adults (Halawani, et.al., 2018). According to (Udovcic et 
al., 2017), hypothyroidism affects approximately four to ten percent of the American population 
while the prevalence of subclinical hypothyroidism is reported to be as high as ten percent. West 
and Felz (2020) report that, up to ten percent of women might experience some sort of deficiency 
of thyroid hormone. Hypothyroidism contributes to heart diseases as its affect’s cardiac 
contractility, and causes destruction of cardiac muscle relaxation, which relates to diastolic 
hypertension and coexistent coronary artery disease (Udovcic et al., 2017). Thyroid hormones 
are important in regulating cardiac, vascular, and metabolic physiology (Udovcic et al., 2017).  
In the studies, Ungvarsky (2019); Bragg et al. (2020) found that most cases of 
hypothyroidism are treated with the use of Synthroid a synthetic compound identical to T4 
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(levothyroxine) produced by the human thyroid gland. In comparison  Armour Thyroid a natural 
product made from animal thyroid glands. The purpose of this paper is to address the question 
whether patients diagnosed with hypothyroidism disease who are taking treatments or those 
requiring the treatment for hypothyroidism would benefit more with levothyroxine compared to 
DTE and whether the levothyroxine monotherapy will lead to overall better outcome over time? 
Is there enough evidence to suggest that one drug is better than the other? Levothyroxine (LT4) 
contain T4 which activates T4 to triiodothyronine (T3), opposite with DTE which has a 
combination therapy of LT4/LT3 (Bragg et al., 2020). In the case of a 42 years old female who 
presented with fatigue, dry skin, weight gain, and sensitivity to cold, as well as the office labs 
that exhibited TSH level of 7.0 and T4 of 0.25, she was started on levothyroxine 25mcg daily 
with a follow up in four weeks. Further research will be conducted to obtain an evidence-based 
recommendation that will guide the decision making whether to continue with levothyroxine or 
to switch her to DTE.  
Case Report 
This was a 42 years-old Caucasian female who presented with the complaints of 
generalized increased sensitivity to cold, fatigue, dry skin, and weight gain. She stated that she 
has been using over the counter moisturizing creams with no improvement to her dry skin. She 
also reports gradual weight increase despite no change in her exercise level or eating habits over 
the course of three months. She reported decrease level of energy leading to decrease 
productivity at work despite the longer sitting hours in the Information Technology department. 
She noticed lack of motivation to exercise. She denied shortness of breath, fever/chills, being 
polyuria, polydipsia or dry mouth, hair loss, constipation, or irregular menses.  
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Medical history revealed that she is currently taking multivitamin one tablet daily and 
probiotics over the counter. She also reported that she is married with two children. She denied 
any medical problems. Her family history included diabetes and hypertension. History of 
surgical procedure was only the wisdom tooth extraction years ago. Physical exam was 
unmarkable with blood pressure 130/80, pulse of 76, temperature of 97.8 °F, and respiratory of 
16. She was well groomed and appropriately dressed for the weather, appearing healthy, alert, 
and oriented to place, person, time, and situation with no identified distress. Ear canals and 
tympanic membrane 's normal and nose and mouth without ulcers or lesions as assessed using 
otoscope. No adenopathy, no asymmetry, masses, or scars noted and no enlargement of the 
thyroid gland to palpation. Lungs clear to auscultation, no rales, rhonchi, or wheezes to both 
upper and lower posterior and anterior lobes. Regular heart rate and rhythm with normal S1 S2, 
no S3 or S4 and no murmur, click, or rub noted. The abdomen was soft, nontender, no masses 
and bowel sound active both quadrants. Denied any symptoms of urinary tract infections or any 
genitourinary abnormalities. Extremities normal, no gross deformities noted, no evidence of 
inflammation in joints, full range of motion in all extremities. Skin was dry with no suspicious 
lesions or rashes. Neurological exam was unremarkable as evidenced by cranial nerves 1-12 
normal and intact mentation and a normal speech. She denied any personal history of psychiatric 
disorders or diagnosis. She denied any history of bleeding or clotting disorder. No Known Drug 
Allergies. 
Office diagnostic test, BHcg was negative, urinary analysis that was normal, complete 
blood count with differential that was normal, metabolic panel that was normal, TSH level of 
7.0, and T4 of 0.25. Based on this assays and clinical manifestations this patient was diagnosed 
with hypothyroidism (E03.9). The treatment plan was a levothyroxine (Synthroid) 25 mcg po 
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daily with follow up for TSH level check in 4 to 6 weeks. In summary this patient is a new 
patient who presented with increased sensitivity to cold and feeling fatigue for the past 3 months 
with weight gain and dry skin. Blood work indicated increased TSH levels suggesting 
hypothyroidism. 
Literature Review 
Based on the studies, the major difference between levothyroxine vs DTE is that 
levothyroxine contains T4 only while desiccated bovine thyroid has T4 and T3 (Bragg et al., 
2020). To clear uncertainty whether the addition of triiodothyronine (T 3, Cytomel) found in 
DTE adds additional benefit to thyroid replacement with thyroxine in treating hypothyroidism 
literature review will be reviewed. This is equally important for further understanding the 
management of hypothyroidism to avoid complications that are associated with undertreatment 
or overtreatment. In some cases, patients who are inadequately treated for hypothyroidism are a 
high risk for cardiac diseases. In addition, increased risk of osteoporosis and atrial fibrillation 
over-replacement of thyroxine is seen in some patients as well (Shim et al., 2019). In comparison 
of levothyroxine vs DTE in management of hypothyroidism several articles will be evaluated.  
In a randomized, double-blind, crossover study at a tertiary care center a study conducted 
on 70 patients ages 18-65 years with a primary diagnose of hypothyroidism was studied (Hoang, 
et al., 2016). These patients previously were treated with DTE then they were switched to 
levothyroxine and their TSH levels was monitored during the treatment course. The aim of the 
study was to examine the effectiveness of DTE compared to levothyroxine among the 
hypothyroidism  patients. The study was conducted in a period of six months and based on the 
results it was concluded that there was no deference in efficacy between the two drugs. The 
patients who were placed on DTE treatment lost 3 pounds. The patients who were previously 
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treated with DTE, did not feel as well despite adequate dose based on serum TSH levels after 
being transferred to levothyroxine. Nearly half of the patients in the study preferred DTE over 
levothyroxine (Hoang, et al., 2016).  
Shomon (2019) completed an online survey that was comprised of 12,146 patients who 
were receiving treatment for hypothyroidism with either levothyroxine alone, levothyroxine 
combined with liothyronine (T3), or DTE. Report indicated that the patients who were taking 
DTE were more content with their treatment than those who were on the other two types of 
therapy (Shomon, 2019). In addition, DTE group described less difficulties with fatigue, weight, 
and memory, than the other two groups (Shomon, 2019). Participants also reported an 
improvement in mood and mental symptoms (Shomon, 2019). Additionally, no improvement in 
body pain, depression, anxiety, quality of life, or body weight in treatment with T4 compared to 
DTE in a 2006 meta-analysis of 11 randomized trials with a total of 1216 patients (Shomon, 
2019). 
Another study was compared levothyroxine to DTE in terms of thyroid blood tests, the 
factors that were considered included changes in weight, psychometric test results and patient 
preference (American Thyroid Association, 2020). An improvement in symptoms with DTE was 
noted among those patients who continued to experience symptoms of hypothyroidism while on 
levothyroxine when they were shifted to DTE (American Thyroid Association, 2020). The report 
indicated  that forty nine percent of the patients preferred DTE, nineteen percent preferred 
levothyroxine and twenty three percent had no preference (American Thyroid Association, 
2020). Again, many patients preferred this DTE option as compared with levothyroxine. No 
differences in thyroid function blood test and psychometric test results, although DTE indicated 
some weight loss (American Thyroid Association, 2020).  
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A cross-sectional survey in 2015 encompassed 337 patients of Lebanese whereby the 
patients were requested to fill the questionnaire in a community setting approached by the 
pharmacist during their visit to obtain levothyroxine drug (El Helou et.al., 2019).The aim of the 
study was to assess treatment adherence to levothyroxine therapy as well as the knowledge of 
these patients regards their disease and treatment therapy including factors concerning their 
adherence to treatment (El Helou et.al., 2019). The study was to provide a complete 
understanding to healthcare providers in improving levothyroxine adherence, understanding the 
draw back and contributing factors was to give insight of levothyroxine for better management 
(El Helou et.al., 2019). Many factors were identified to affect adherence, such as higher monthly 
income, comorbidities, history of thyroidectomy. Patients in this study, did not report side effects 
or negative effectiveness with the use of levothyroxine (El Helou et.al., 2019).  
In another randomized study on levothyroxine treatment for subclinical hypothyroidism, 
finding discouraged routine use of levothyroxine on adults 80 years and older (Peeters et al., 
2019). The trials were done between April 2013 and May 2018, with final follow up May 
4,2018. In another study levothyroxine treatment was compared with placebo, symptoms such as 
fatigue and did not significantly affect the outcome (American Thyroid Association, 2020). 
When comparing levothyroxine and DTE dosing, there is a huge problem due to lack of 
standardization for each batch to be administered (Mooijaart et al., 2019). The preparations of 
DTE do not dose strength in milligrams, but relatively in grains of thyroid (Mooijaart et al., 
2019).  
According to Udovcic et al.(2017), there is no actual known of the milligram equivalent 
in each dose, Natural vs. Synthetic Thyroid Medications for Thyroid. Lastly, DTE is not 
recommended for older adults. It is considered high risk in those older than 65 years by 
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government health groups. Medicare does not cover it due to its dangerous in causing atrial 
fibrillation in older people with heart problems (Udovcic et al., 2017). 
The impact of addition of T3 is minimal in managing hypothyroidism. According to T et 
al. (2020), in a study with elderly patients, issues with persistent neurocognitive dysfunction 
would benefit from the addition of T 3 at a dose of 125 mcg, with a simultaneous decrease in the 
T 4 dose of 50 mcg in comparison to younger patients ages 29-44. The study failed to find any 
benefits of partial T 3 substitution while the doses of T 4 was sufficient to reestablish TSH levels 
to normal levels (T et al., 2020). The study concluded that routine use of T 3 cannot be 
recommended, but it be can be used on elderly patients with lingering confusion, depression, or 
slow mentation along with the adequate doses of T 4 (T et al., 2020). American Thyroid 
Association and European Thyroid Association recommend a trial of combination therapy for 
patients on single therapy with thyroxine alone who are continually discontented with their 
therapy (T et al., 2020). 
In a survey addressing the treatment of hypothyroidism with American Thyroid 
Association (ATA) members, involved physicians who presented with thirteen theoretical 
patients and treatment options included levothyroxine, synthetic combination therapy, thyroid 
extract, and liothyronine monotherapy Ungvarsky (2019). The purpose was to analyze 
prescribing levothyroxine monotherapy vs. any T3 therapy. The factors considered were control 
of time and physician characteristics choice of therapy and the country of practice. The survey 
concluded that current North American guidelines do not recommend combination therapy 
(Jacqueline et al., 2019). According to Ungvarsky (2019); Bragg et al. (2020), levothyroxine is 
one of the most repeatedly prescribed drugs that is considered the primary treatment around the 
world for hypothyroidism related to low production of thyroxine among patients (Bragg et al., 
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2020). It is also utilized to replace the natural hormone in patients whose thyroid gland has been 
removed in conditions like cancer (Halawani, 2018). According to McAninch and Bianco 
(2019), levothyroxine monotherapy is favored because of less safety concerns and its efficacy to 
stabilize the TSH serum levels. 
Finally, natural thyroid preparations (DET) were the first pharmacologic treatments 
accessible with a reported thyrotoxic adverse effects and issues with inconsistencies in the 
strength of the tablets surfaced (McAninch & Bianco, 2016). In addition, it was discovered that 
some contained anywhere from double to no visible metabolic activity, and other concerns  the 
shelf-life of desiccated tablets was limited especially with moist conditions impacting treatment 
not responding to desiccated thyroid altogether due to inactive thyroid hormone (McAninch & 
Bianco, 2016). Because of the mentioned problems the reputation of natural thyroid products 
was blemished because there was hesitation to use levothyroxine monotherapy in fear of 
resulting T3 deficiency but it was discovered later that prescribing T4 there was conversion to T3 
(McAninch & Bianco, 2016).This set the foundation for treatment with levothyroxine in 
replacing thyroid hormone to in hypothyroidism with the aid of TSH radioimmunoassay a major 
shifted toward levothyroxine monotherapy as first-line therapy (McAninch & Bianco, 2016). 
TSH offered the first sensitive and specific marker of systemic thyroid hormone status. 
Clinicians use TSH levels to titrate therapy to achieve normal levels of serum. In contrast, 
desiccated thyroid resulted in a T3 peak about 2 to 5 hours after administration that related to 
thyrotoxic symptoms in some patients. A single daily dose of levothyroxine develops in stable 
blood levels of T4 and T3 throughout the day. This gave weight in using levothyroxine over 
DTE (McAninch & Bianco, 2016). 
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Analysis/ Conclusion 
Studies indicate benefit of weight loss with the use of DTE.  Findings also indicate large 
numbers of patient preferred the use of DTE when comparing with levothyroxine based on 
symptoms experienced. (Hoang et al., 2013; (American Thyroid Association, 2020); Udovcic et 
al., 2017). Several impediments were witnessed with DTE. It was discovered that there is a high 
risk with the use of DTE when compared to levothyroxine in adults over the age of 65 years with 
heart problems (Peeters et al., 2019). Moreover, inaccurate dosage is associated with DTE. 
Furthermore, DTE was developed before the U.S. Food and Drug Administration (FDA) existed 
(Shomon, 2019). It was among grandfathered prescription, regulated by FDA but, not the same 
required application process for new drugs introduced to the market (Shomon, 2019). 
Learning Points 
➢ No significant improvement with the use of DTE therapy, no increase in quality of life; 
however, DTE contributed to modest weight loss. 
➢ There is need for educational programs to implemented, doctor-patient and pharmacist-
patient relationship could be improved, and new treatment regimens be considered in 
order to enhance patient adherence. 
➢ Most people do well on the standard treatment of levothyroxine, though some people will 
have hypothyroid symptoms and/or low T3 levels while taking it, even though their TSH 
levels are within normal limits. 
➢ Treatment with T4 only appears to be completely sufficient for the great majority of 
people with hypothyroidism, although some individuals are likely to feel better with 
combination treatment. 
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➢ It is not advisable to use synthetic or natural, thyroid hormones to treat obesity or to help 
with weight loss. People with normal thyroid function will not benefit from thyroid 
hormone taking in losing weight. Serious and potentially life-threatening complications 
with taking too much thyroid hormone or using it along with other weight loss drugs. 
➢ DTE is considered high risk in those older than 65 years by government health groups. It 
is also, not covered by Medicare due to it dangerous in causing atrial fibrillation in older 
people with heart problems.  
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